Please provide your email address to receive an email when new articles are posted on . Two-thirds of respondents said patients had near or complete symptom resolution after Xiidra treatment. Mild or ...

This advertising content was written by the Bausch + Lomb team, and does not reflect the opinions or point of view of Vox Media or Vox Creative. Do you find yourself frequently reaching for ...

Bausch & Lomb announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based milestone ...

ZURICH (Reuters) - Swiss drugmaker Novartis has withdrawn an application for European approval of its Xiidra dry eye medicine after regulators concluded its effectiveness had not been demonstrated and ...